Centene has sold off Magellan Rx to Prime Therapeutics for $1.5 billion, a move that will add Magellan's specialty drug management to Prime's pharmacy benefit management tools. The end result, the ...

Centene has completed its $1.35 billion divestiture of Magellan Rx to Prime Therapeutics. The move adds Magellan's specialty drug management capabilities to Prime Therapeutics' suite of pharmacy ...

Prime Therapeutics will pay $1.35 billion to acquire Magellan Rx Management, a pharmacy organization that manages specialty drugs for patients with complex health conditions and works with many state ...

The combination creates an opportunity to transform the industry by driving affordability and integrating whole-person care to enhance the patient, provider and customer experience. EAGAN, Minn., Dec.